AIM ImmunoTech targets Q1 2027 topline data for Phase 2 DURIPANC trial of Ampligen plus AstraZeneca’s Imfinzi in pancreatic cancer
Bitget2026/09/22 12:55- AIM ImmunoTech highlighted Ampligen’s potential role in pancreatic cancer, including use alone or in combination with other therapies.
- Prior data from a Dutch named-patient program were cited as showing longer survival for selected patients versus historical controls, without detailing new trial results.
- A Phase 2 DURIPANC study testing Ampligen with AstraZeneca’s Imfinzi is ongoing in patients with stable disease following FOLFIRINOX.
- Topline DURIPANC results are expected in Q1 2027, with a more detailed overall-survival analysis slated for Q3 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Crypto prices
More
